Table 4 Prosthetic heart valve related complications
From: Mid-term follow-up and outcomes of patients with prosthetic heart valves: a single-centre experience
Complication | Valve type and position | |||||
|---|---|---|---|---|---|---|
Biological AVR (N = 192) | Mechanical AVR (N = 46) | Biological MVR (N = 13) | Mechanical MVR (N = 3) | MV repair ± annuloplasty ring (N = 26) | Transcatheter aortic valve implantation (N = 14) | |
30-day mortality | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Valve thrombosis | 0 (0) | 0 (0) | 0 (0) | 1 (33.3) | 0 (0) | 0 (0) |
Bleeding event | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Structural dysfunction | 1 (0.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Non-structural dysfunction—stenosis | 1 (0.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
Significant PHV regurgitation with a change in NYHA | 1 (0.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
PHV infective IE | 11 (5.7) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
PHV IE requiring re-do | 1 (0.5) | 0 (0) | 0 (0) | 1 (33.3) | 0 (0) | 0 (0) |
Re-do for altered PHV function | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
PHV related mortality | 4 (2.0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |